On 15 November 2024, Canada’s Drug Agency (CDA-AMC) published its final recommendation for Eli Lilly’s Ebglyss™ (lebrikizumab), recommending against reimbursement of Ebglyss™ by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older.
On 19 November 2024, Eli Lilly published a statement expressing disappointment and “strong disagreement” with the CDA-AMC’s recommendation. Kenneth Custer, General Manager for Lilly Canada, stated that the CDA-AMC’s recommendation is “inconsistent with all other HTA bodies that have reviewed Ebglyss”, and that “repeat misalignment with other domestic and international HTA agencies does not establish Canada as a predictable or competitive market for innovative medicines”.
Ebglyss™ was approved by Health Canada in June 2024 and received a positive reimbursement recommendation with conditions by the L’Institut National d’Excellence en Santé et Services Sociaux (INESSS) as a first line biological therapy in Quebec. Ebglyss™ has also received positive recommendations in the EU (September 2023), UK, France and Australia (July 2024).
In October 2024, Eli Lilly announced positive results from the Phase 3b ADapt study, which demonstrated that Ebglyss™ improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with dupilumab.